Exane Derivatives’s Tvardi Therapeutics TVRD Stock Holding History

Exane Derivatives’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-24	Closed	-$10.6K	–	1047
2022 Q1	$10.6K	Hold	24	–	–	﹤0.01%	674
2021 Q4	$10.6K	Hold	24	–	–	﹤0.01%	589
2021 Q3	$13.5K	Hold	24	–	–	﹤0.01%	700
2021 Q2	$11.8K	Sell	24 -6	-20%	-$3.8K	﹤0.01%	737
2021 Q1	$23.6K	Sell	30 -14	-32%	-$9.58K	0.01%	559
2020 Q4	$24.2K	Hold	44	–	–	0.01%	505
2020 Q3	$20.4K	Hold	44	–	–	0.01%	440
2020 Q2	$27.4K	Hold	44	–	–	0.01%	385
2020 Q1	$21.1K	Sell	44 -180	-80%	-$97.8K	0.01%	405
2019 Q4	$136K	Sell	224 -276	-55%	-$194K	0.03%	287
2019 Q3	$329K	Sell	500 -56	-10%	-$46.6K	0.06%	193
2019 Q2	$430K	Buy	556 +367	+194%	+$258K	0.08%	185
2019 Q1	$133K	Sell	189 -11	-6%	-$6.58K	0.03%	266
2018 Q4	$93.6K	Hold	200	–	–	0.02%	324
2018 Q3	$172K	Hold	200	–	–	0.03%	261
2018 Q2	$138K	Buy	+200	New	+$102K	0.02%	294

Other funds holding TVRD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exane Derivatives's TVRD Position: Q2 2022 in Review

Exane Derivatives sold out of Tvardi Therapeutics (TVRD) in Q2 2022, closing a stake of 24 shares — an estimated $10.6K sold.

Exane Derivatives first reported a position in TVRD in Q2 2018 and held it in 16 quarters. The position peaked at $430K in Q2 2019. 179 funds tracked by Wall St. Rank hold TVRD as of Q2 2022.

Exane Derivatives reported no remaining Tvardi Therapeutics position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 24 Tvardi Therapeutics shares in Q2 2022, an estimated $10.6K.
Exane Derivatives first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 16 quarters.
Exane Derivatives's Tvardi Therapeutics position peaked at $430K in Q2 2019.
179 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.